The association between age-related macular degeneration and renal cell carcinoma: a nested case-control study
Menée au Royaume-Uni à partir de données portant sur 1 547 patients atteints d'un carcinome à cellules rénales et sur 6 066 témoins, cette étude évalue l'association entre une dégénérescence maculaire liée à l'âge et le risque de développer la maladie (durée médiane de suivi : 6 ans)
Background: Overexpression of vascular endothelial growth factor is implicated in the pathogenesis of both renal cell carcinoma (RCC) and age-related macular degeneration (AMD). We evaluated the association between age-related macular degeneration and RCC risk.
Methods: We conducted a matched case-control study within a population-representative database from the United Kingdom (UK). Study cases were defined as individuals with any diagnostic code of RCC. For every case, four eligible controls were matched on age, sex, practice site, calendar time and duration of follow-up. Exposure of interest was diagnosis of AMD prior to cancer diagnosis. Adjusted odds ratios (ORs) and 95% confidence intervals (CIs) for RCC were estimated using conditional logistic regression. In a secondary analysis, we evaluated the association between other retinopathies and RCC and AMD and the hypovascular pancreatic cancer.
Results: The study population included 1,547 patients with RCC and 6,066 matched controls. Median follow-up time was 6 years (IQR 3-9). AMD diagnosis was associated with a significantly increased RCC risk (OR 1.89, 95%CI 1.09-3.29). In contrast, there was no association between other retinopathies and RCC risk (OR 0.8, 95%CI 0.56-1.15). AMD was associated with a lower risk for pancreatic cancer (OR 0.47, 95%CI 0.35-0.64).
Conclusions: Patients with AMD may be at higher risk for RCC. Providers should be aware of this potential link and consider screening for RCC within this population.
Impact: Providers should be aware of the potential link between AMD and RCC
Cancer Epidemiology Biomarkers & Prevention , résumé, 2016